Hongyun Zhao (Qun Chen)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Journal for immunotherapy of cancer

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Fan Luo, Jiaxin Cao, Hongyun Zhao, Lusha Liu, Ting Yang, Xue Bai, Wenjuan Ma, Chaozhuo Lin, Ting Zhou, Jianhua Zhan, Yan Huang, Yunpeng Yang, Hongyun Zhao, Li Zhang
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype. Journal for immunotherapy of cancer 12 (6) (2024)
Fan Luo, Jiaxin Cao, Hongyun Zhao, Lusha Liu, Ting Yang, Xue Bai, Wenjuan Ma, Chaozhuo Lin, Ting Zhou, Jianhua Zhan, Yan Huang, Yunpeng Yang, Hongyun Zhao, Li Zhang
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype. Journal for immunotherapy of cancer 12 (6) (2024)
Fan Luo, Jiaxin Cao, Hongyun Zhao, Lusha Liu, Ting Yang, Xue Bai, Wenjuan Ma, Chaozhuo Lin, Ting Zhou, Jianhua Zhan, Yan Huang, Yunpeng Yang, Hongyun Zhao, Li Zhang
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype. Journal for immunotherapy of cancer 12 (6) (2024)
Yuxiang Ma, Qun Chen, Yang Zhang, Jinhui Xue, Qianwen Liu, Yuanyuan Zhao, Yunpeng Yang, Yan Huang, Wenfeng Fang, Zhiguo Hou, Shaorong Li, Jing Wang, Li Zhang, Hongyun Zhao
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study. Cancer chemotherapy and pharmacology (2023)